Coronary Heart Disease – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of CHD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of acute coronary syndrome for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s CHD forecast will answer the following questions:
- How will improvements in survival change the number of people living with a diagnosis of CHD?
- Of all people diagnosed with CHD how many in each country across the world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CHD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but they may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following CHD subpopulations:
- Stable Angina scheme – Diagnosed prevalent cases with stable angina
- Stable Angina scheme – Diagnosed prevalent cases with no stable angina
- … and more (details available on request).
Note: Coverage may vary by country.
Ansuman Swain, B.D.S., M.P.H., Epidemiologist, Epidemiology. As part of his M.P.H. curriculum, he worked as an intern at the National Health Mission in Odisha, India, where he observed the implementation of the RBSK program. Mr. Swain is a graduate in dentistry from KIIT University in Odisha and holds an M.P.H. degree from Manipal Academy of Higher Education in Karnataka, India, with a specialization in global health from Maastricht University in the Netherlands.
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.